antibody therapy in all: how and why to integrate antibody-based treatment into patient management
Published 3 years ago • 86 plays • Length 1:33:36Download video MP4
Download video MP3
Similar videos
-
35:13
reaching the next level of myeloma patient care: antibody therapy and novel mechanisms of action
-
56:44
treatment innovation in dlbcl: real-world insight on integrating antibodies and cellular therapy
-
40:12
improving patient outcomes in urothelial carcinoma with novel antibody–drug conjugates
-
1:20:04
antibodies in multiple myeloma: insights and patient voices along the therapeutic journey
-
1:08:35
innovative therapy in multiple myeloma: monoclonal antibodies and bcma and non-bcma options
-
56:15
changing times in dlbcl and practicalities of antibody therapy
-
1:04:53
breaking therapeutic barriers with novel antibodies in rrmm
-
54:38
bcma antibodies and cellular therapies in rrmm
-
1:03:24
bladder cancer: understanding immune-, targeted-, and antibody-based models for patient care
-
57:18
translating progress with immunotherapies and targeted agents into improved outcomes in tnbc
-
1:23:36
collaborative care and next steps with adjuvant and neoadjuvant immunotherapy for melanoma
-
32:28
an "off-the-shelf" approach for myeloma care: bcma antibodies
-
1:02:26
myeloma care: pharmacy perspectives on antibodies and bcma car-t
-
3:33
in-depth: what are monoclonal antibodies and how do they work?
-
1:00:29
answers to key questions about antibody–drug conjugates in nsclc
-
56:08
gaining confidence in predicting and assessing response to cancer immunotherapies
-
55:21
the rise of novel antibodies in multiple myeloma
-
3:20
how monoclonal antibodies treat cancer
-
3:33
covid-19 update: monoclonal antibody treatment